Haemonetics Prices Upsized Private Placement of $600M Of 2.50% Convertible Senior Notes Due 2029
Portfolio Pulse from Benzinga Newsdesk
Haemonetics Corporation has announced the pricing of an upsized private placement of $600 million of 2.50% convertible senior notes due 2029.

May 23, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics Corporation has successfully priced an upsized private placement of $600 million of 2.50% convertible senior notes due 2029. This move is likely to provide the company with additional capital for growth and operational needs.
The successful pricing of the upsized private placement indicates strong investor confidence and provides Haemonetics with significant capital. This can be used for growth initiatives, debt repayment, or other operational needs, which is generally positive for the company's financial health and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100